Zoetis Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Zoetis Inc 's ROA in the third quarter of 2026?
Zoetis Inc achieved a return on average assets (ROA) of 16.36 % in its third quarter of 2026, this is above ZTS's average return on assets of 13.13%.
Zoetis Inc s assets during the 12 months ending in the third quarter of 2026 are valued at $15 billion

ROA decreased relative to the period ending Jun 30 2026, due to the decline in net income.

However, within the Healthcare sector 57 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 280, from total ROA ranking in the second quarter of 2026 at 305.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	1.47 %	6.35 %	9.19 %	10.34 %	5.19 %
Y / Y Net Income Change	-18.03 %	-4.82 %	-0.17 %	3.79 %	4.19 %
Net Income (TTM) in million	2,486	2,616	2,651	2,652	2,630
Return On Assets (TTM)	16.36 %	17.28 %	17.77 %	18.17 %	18.48 %
ZTS's Total Ranking	# 280	# 305	# 275	# 268	# 278
Total Assets (TTM) in million	15,086	15,077	15,154	15,467	14,867
Seq. Total Assets Change	0.06 %	-0.51 %	-2.02 %	4.04 %	4.87 %
Seq. Net Income Change	-14.47 %	14.98 %	-0.33 %	-16.37 %	-0.69 %

ZTS's 5 Years Annual ROA >> Back to ZTS Management Effectiveness >> Compare ZTS ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 28
Sector	# 58
Overall	# 281

Return On Assets Statistics
High	Average	Low
18.2 %	13.13 %	4.91 %
(Jun 30 2025)		(Dec 31 2015)

Financial Statements
Zoetis Inc 's Assets	$ 15,086 million	ZTS's Balance sheet
Zoetis Inc 's Income	$ 591 million	Quarterly ZTS's Income Statement
ZTS's Income by Division		See ZTS's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	10.34 %	-0.27 %	-4.41 %	7.19 %	2.25 %
Total Assets in million	15,467	14,018	14,056	14,705	13,719
Y / Y Net Income Change	7.09 %	6.67 %	10.85 %	3.79 %	24.33 %
Net Income in million	2,673	2,496	2,340	2,111	2,034
Annual Return On Assets	17.28 %	17.81 %	16.65 %	14.36 %	14.83 %

ZTS's 5 Years Annual ROA >> Back to ZTS Management Effectiveness >> Compare ZTS ROA to its Competitors

Comment on ZTS's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA deteriorated to 17.28 %, despite annual net income growth of 7.09 % to $2,673.00 million, from $2,496.00 million a year ago, as ZTS's assets increase to $15,467.00 million, by 7.09 %.

More Return On Assets Ratios
ZTS's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ZTS's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ZTS's Competitors
Subscribers only: Roa for Zoetis Inc 's Suppliers
Subscribers only: Return On Assets for ZTS's Customers

You may also want to know
ZTS's Roi	ZTS's Inventory Turnover Ratio	ZTS's Growth Rates	ZTS's Dividend Comparisons
	ZTS's Profitability Ratios	ZTS's Asset Turnover Ratio	ZTS's Dividend Growth
ZTS's Roe	ZTS's Valuation Ratios	ZTS's Financial Strength Ratios	ZTS's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector	ROA
Ironwood Pharmaceuticals inc	42.53 %
Aurinia Pharmaceuticals Inc	40.63 %
Nurix Therapeutics Inc	38.61 %
Indivior Pharmaceuticals Inc	36.35 %
Rallybio Corporation	34.55 %
Idexx Laboratories Inc	34.05 %
Zevra Therapeutics Inc	26.33 %
Caredx Inc	25.74 %
Medpace Holdings Inc	24.47 %
Acadia Pharmaceuticals Inc	21.60 %
Standard Biotools Inc	21.56 %
Eli Lilly And Company	21.24 %
Iradimed Corporation	20.89 %
Resmed Inc	18.67 %
Alector Inc	18.37 %
Corcept Therapeutics Inc	18.09 %
Chemed Corporation	17.73 %
Halozyme Therapeutics Inc	17.26 %
Pro dex Inc	16.75 %
Denali Therapeutics Inc	16.42 %
Krystal Biotech Inc	15.48 %
West Pharmaceutical Services Inc	15.47 %
Dexcom Inc	15.47 %
Intuitive Surgical Inc	14.71 %
Vertex Pharmaceuticals Inc	14.16 %
Neurocrine Biosciences Inc	13.69 %
Illumina Inc	13.43 %
Healthcare Services Group Inc	12.79 %
Kiniksa Pharmaceuticals International Plc	12.64 %
Tenet Healthcare Corp	12.39 %

Date modified: 2026-11-06T12:59:59+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.